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Introduction
Combination antiretroviral therapy (cART) is the mainstay 
of treatment in HIV. It has improved the morbidity and 
mortality associated with HIV, turning it into a chronic dis-
ease. However, cART, together with the virus itself, 
increases the risk of various metabolic complications, 
including obesity,1 type 2 diabetes mellitus (T2DM) and 
cardiovascular disease (CVD).2 Indeed, CVD is the lead-
ing cause of death in HIV-infected patients on cART with 
a linear increase in the incidence of myocardial infarction 
observed with long-term cART exposure.3
Insulin resistance (IR) is central to the development of 
cardiometabolic disease,4 being present in 21% of HIV 
patients on antiretroviral (ARV) therapy.5 In vitro as well 
as single-drug studies in both healthy6 and HIV-infected 
patients7 have shown that IR can be induced by both pro-
tease inhibitors (PIs) and nucleoside reverse transcriptase 
inhibitors (NRTIs). Although newer ARVs are increas-
ingly used in clinical practice, IR still remains an impor-
tant problem; HIV patients (n = 328) randomised to 
tenofovir disoproxil fumarate/lamivudine (TDF/3TC) with 
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either boosted atazanavir (ATV) or boosted darunavir or 
raltegravir showed a 1.9-fold increase in homeostatic 
model assessment–IR (HOMA-IR) within 4 weeks.8 
Importantly, HIV-associated metabolic disease results in 
increased healthcare burden; a recent study in the United 
States identified the management of IR/diabetes to be the 
biggest contributor to the cost burden and resource use 
among all HIV-related adverse events studied.9
Adipose tissue is an important determinant of IR and 
may therefore play a key role in cART-associated meta-
bolic disease. Adipose tissue has also been shown to be a 
reservoir for HIV and a source of chronic inflammation.10 
Clinical interventions to arrest or reverse cART-associated 
adipose-mediated IR are a potential strategy to reduce the 
incidence of T2DM and CVD in HIV-positive patients. To 
this end, insulin sensitisers such as thiazolidinediones and 
metformin have been trialled, but results from randomised 
clinical trials in HIV-positive patients have been disap-
pointing and sometimes deleterious.11–13 There is therefore 
a need for novel clinical interventions that can reduce 
cART-induced IR in HIV-positive individuals.
Preliminary in vitro studies have suggested that tel-
misartan (TEL), an angiotensin II receptor blocker (ARB), 
reduces cART-induced adipose dysfunction by inhibition 
of the renin–angiotensin system (RAS).14 In addition to 
being an ARB, TEL is also a partial agonist at the peroxi-
some proliferator receptor-gamma (PPARγ) receptor,15 a 
key regulator of adipose tissue metabolism.16 In this arti-
cle, we further evaluate the effect of TEL on cART-induced 
adipocyte dysfunction and IR in a novel chronic in vitro 
toxicity model, in addition to assessing its concentration–
response relationship.
Materials and methods
Materials
Murine 3T3-F442A cells were a kind gift from Prof Karen 
Chapman (University of Edinburgh). Primary human 
abdominal subcutaneous preadipocytes were obtained 
commercially from age- and sex-matched healthy donors 
(n = 3; body mass index < 25 kg/m2; Promocell, Heidelberg, 
Germany). Collection of adipose tissue was approved by 
local ethics committee and all donors gave informed con-
sent. None of the donors had any known medical condi-
tions (i.e. hypertension, CVD, thyroid disorders, renal 
disorders, diabetes or chronic pain conditions) or were on 
endocrine, anti-inflammatory, statin, thiazolidinedione or 
antihypertensive therapy. Lopinavir (LPV), ritonavir 
(RTV), ATV and rosiglitazone (ROSI) were purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA) and 
TEL was provided by Boehringer Ingelheim GmbH 
(Ingelheim, Germany). Adipocyte media were obtained 
from PromoCell. TaqMan gene expression assays [PPARγ 
and lipin 1 (LPIN1)] and TaqMan Gene Expression Master 
Mix were purchased from Life Technologies Ltd (Paisley, 
UK). Singleplex and multiplex enzyme-linked immuno-
sorbent assays (ELISAs) for adipokines [adiponectin, 
interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) 
and resistin] were obtained from Merck Millipore 
(Hertfordshire, UK) and Life Technologies Ltd. A colori-
metric assay for free fatty acid release was obtained from 
Abcam (Cambridge, UK). Estimation of phospho-Akt 
(pAktSer473) and total Akt was performed by sandwich 
ELISA kits obtained from Thermo Fisher Scientific 
(Paisley, UK).
Methods
In vitro chronic adipocyte toxicity model: ARVs accumulate 
extensively within the adipocytes,10 and thus, we used a chronic 
in vitro toxicity model to mimic this. Briefly, both 3T3-F442A 
murine cells and primary human subcutaneous adipocytes 
were cultured, induced to differentiate as described 
previously,17 and treated with PIs with or without TEL 
and/or ROSI throughout adipocyte differentiation. For 
3T3-F442A, the cells were cultured with Dulbecco’s Mod-
ified Eagle’s medium (Sigma-Aldrich, Dorset, UK) and 
10% foetal calf serum followed by the initiation of differ-
entiation using 10 mg/mL insulin (Sigma-Aldrich). Pri-
mary human preadipocytes were cultured in a Preadipocyte 
Growth Medium which is a low-serum (5% v/v) medium 
optimised for the expansion of human preadipocytes. Once 
the cells became 70%–80% confluent, differentiation was 
induced by culturing them in the Preadipocyte Differentia-
tion Medium, a serum-free medium, for 3 days followed 
by further maintenance of differentiating adipocytes in the 
Adipocyte Nutrition Medium. Drug treatment was started 
48 h post initiation of differentiation and carried out every 
48 h over a period of 10 days (or 12 days in the case of pri-
mary human adipocytes). The effects of PIs were tested 
over a wide concentration range (1–20 µM) including their 
near-Cmax values (RTV and LPV: 10 µM; ATV: 4.4 µM). 
We initially selected two different concentrations of TEL 
(1 and 5 µM) based on the previous literature;14,18 but for 
further dose characterisation of TEL, we tested a range of 
concentrations (0.5–20 µM). TEL was coincubated with 
each of the PIs and added at the same time. ROSI (10 µM), 
a PPARγ agonist, was coincubated with LPV only in the 
primary human adipocyte model as a comparator.
Measurement of cell viability. Viability of differentiating 
3T3-F442A and primary human adipocytes was assessed 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay. MTT measures mitochon-
drial metabolism as a surrogate marker of cell viability.19 
The cells were incubated with the ARVs at serial concen-
trations (0.01–100 µM) for 4 days. On day 4, the cells were 
incubated with MTT and the absorbance of the resultant 
formazan product was measured at 560 nm.
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Lipid accumulation assay. Lipid accumulation in differenti-
ating adipocytes was assessed on day 10 (3T3-F442A 
cells) or day 12 (primary human adipocytes) of differentia-
tion using Oil Red O (Sigma, Dorset, UK) as previously 
described.14 Lipid-bound dye was extracted using 70% 
isopropyl alcohol and staining was quantified at 520 nm. 
The drug-treated cells were compared against the vehicle-
treated control (methanol).
RNA extraction and gene expression. Total RNA was iso-
lated using the RNeasy kit (Qiagen, Manchester, UK). 
Total RNA was reverse transcribed using the TaqMan® 
reverse transcription kit (Life Technologies Ltd). Gene 
expression of PPARγ and LPIN1 were assessed by real-
time polymerase chain reaction (PCR) using TaqMan 
Assays-on-Demand gene expression assays on a 7900HT 
Fast Real-Time PCR System (Life Technologies Ltd).
Assessment of lipolysis. Free fatty acid concentration in the 
conditioned media of primary human adipocytes was 
determined using the Free Fatty Acid Quantification Assay 
Kit as per manufacturer’s instructions (Abcam). Briefly, 
palmitic acid standard (1 nmol/µL) was used to prepare the 
standard curve dilution; the reaction plates were prepared 
and incubated in the dark at room temperature for 30 min 
and the absorbance was measured using a microplate spec-
trophotometer (Beckman Coulter DTX880 Multimode 
Detector) at 595 nm.
Estimation of adipokines. Adipokine (adiponectin, IL-6, 
resistin and TNF-α) concentrations in the conditioned 
media were determined on day 10 (3T3-F442A) or day 12 
(primary human adipocytes) post differentiation using 
bead-based Milliplex Mouse Sandwich Multiplex ELISA 
kits (Merck Millipore) and Human Singleplex ELISA kits 
(Life Technologies Ltd), respectively. The ELISA kits 
used had the following detection limits: adiponectin, 
5.2 pg/mL (murine) and 100 pg/mL (human); IL-6, 5.3 pg/
mL (murine) and < 1 pg/mL (human); TNF-α, 11.2 pg/mL 
(murine) and < 2 pg/mL (human) and resistin, 6.1 pg/mL 
(murine) and 10 pg/mL (human).
Estimation of phosphorylated Akt content. Phosphorylated 
Akt (serine residue 473) as well as total Akt was quanti-
tated by a sandwich ELISA, as recommended by the man-
ufacturer (Thermo Fisher Scientific). Briefly, the diluted 
lysates were applied to 96-well plates containing immobi-
lised monoclonal antibodies specific for human Akt and 
incubated for 2 h at room temperature. A pS473 Akt stand-
ard and the samples were pipetted into the wells, followed 
by washing and incubation with a rabbit antibody (Cell 
Signalling, MA, USA) specific for AKT phosphorylated at 
serine 473. Following washing, a horseradish peroxidase-
labelled anti-rabbit IgG was added and washed; a substrate 
solution [3,3′,5,5′-tetramethylbenzidine (TMB)] was 
added to produce colour and the absorbance was read at 
450 nm.
Statistical analysis
Data are presented as mean ± standard deviation (SD) for 
at least three independent experiments to ensure repro-
ducibility. Statistical significance was determined using 
the non-parametric Mann–Whitney U test (IBM SPSS 
Statistics, version 22). The threshold of significance was 
set at p < 0.05.
Results
ARVs cause adipocyte cytotoxicity
Cytotoxicity was observed with all ARVs during differen-
tiation of preadipocytes and followed a similar trend in 
both 3T3-F442A and primary human cells. In differentiat-
ing 3T3-F442A adipocytes, the rank order for cytotoxicity 
was LPV (IC50 = 14 µM) > RTV (IC50 = 48 µM) > ATV 
Figure 1. Cytotoxicity profile of protease inhibitors 
in differentiating (a) 3T3-F442A and (b) primary human 
adipocytes. Data are expressed as mean (n = 3) ± SD.
RTV: ritonavir; LPV: lopinavir; ATV: atazanavir.
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(IC50 = 66 µM; Figure 1(a)). In primary human adipocytes 
undergoing differentiation, the rank order for cytotoxicity 
was LPV (IC50 = 28 µM) > RTV (IC50 = 38 µM) > ATV 
(IC50 = 84 µM; Figure 1(b)).
TEL reverses ARV-induced inhibition in 
adipocyte lipid accumulation
In 3T3-F442A adipocytes, a dose-dependent reduction in 
lipid accumulation was observed for LPV (at 20 µM, a 
reduction of 32% in mean absorbance, p < 0.01) and RTV 
(at 20 µM, 44% reduction, p < 0.01) but not for ATV [at 
20 µM, 4% increase, non-significant (NS)] in comparison 
with the vehicle-treated controls (Figure 2(a); full concen-
tration response data are given in Supplementary 
Information); 1 µM TEL partially reversed (p = 0.01) the 
RTV- and LPV-induced reduction in lipid accumulation in 
3T3-F442A adipocytes (Figure 2(a)).
In primary human adipocytes, LPV and RTV (40% 
and 55% decrease, respectively, in comparison with the 
vehicle-treated control, p < 0.01) but not ATV (9% 
increase; NS) inhibited lipid accumulation (Figure 2(b)). 
Both TEL (5 µM) and ROSI (10 µM) reversed (p < 0.01) 
the ARV-induced inhibition of lipid accumulation partially 
in primary human adipocytes (Figure 2(b)). The effect 
shown by ROSI was stronger than that by TEL.
TEL reverses ARV-induced downregulation of 
PPARγ and LPIN1 gene expression
PPARγ. In 3T3-F442A adipocytes, both LPV and RTV 
(75% and 73% downregulation, respectively, p < 0.01), 
but not ATV, downregulated PPARγ gene expression in 
comparison with the vehicle-treated control. This was par-
tially but significantly reversed by 1 µM TEL (Figure 3(a)). 
A similar result was observed in primary human adipo-
cytes (LPV and RTV with 78% and 80% downregulation, 
respectively) which was partially reversed by 5 µM TEL 
(LPV + TEL, p = 0.03; RTV + TEL, p = 0.01; Figure 3(b)).
LPIN1. Both LPV and RTV downregulated LPIN1 gene 
expression in both 3T3-F442A adipocytes (LPV, 64%; 
RTV, 78%, p < 0.01; Figure 3(c)) and primary human adi-
pocytes (LPV, 68%; RTV, 63%, p < 0.01; Figure 3(d)). In 
both models, this was partially reversed by 1 (3T3-F442A) 
or 5 µM (primary human adipocytes) TEL (Figure 3(c) and 
(d)). ATV did not have any effect on LPIN1 expression.
TEL reverses ARV-induced changes in adipokine 
secretion
Adiponectin. In 3T3-F442A adipocytes, both LPV (4.0 ng/
mL ± 0.4; p = 0.002) and RTV (7.0 ± 1.0; p = 0.001) but 
not ATV (14.2 ± 2.4) caused downregulation in secreted 
adiponectin protein in comparison to the vehicle-treated 
control (16.5 ± 2.0; Figure 4(a)). 1 µM TEL resulted in a 
significant but partial reversal of PI-induced downregula-
tion of adiponectin (Figure 4(a)). A similar result was 
observed in primary human adipocytes (LPV, 88% reduc-
tion, p = 0.01; RTV, 73% reduction, p = 0.01; ATV, 7.5% 
reduction, NS); both TEL (5 µM) and ROSI (10 µM) were 
able to significantly reverse PI-induced downregulation of 
adiponectin (Figure 4(b)).
IL-6. Both LPV and RTV but not ATV increased the 
secretion of IL-6 in 3T3-F442A adipocytes (LPV, 190 ng/
mL ± 11.3; RTV, 243 ± 7.9; both p < 0.01; ATV: 55 ± 8.0, 
NS) in comparison to the vehicle-treated control (45 ± 7.1; 
Figure 4(c)). A similar effect was also observed in primary 
human adipocytes for these PIs (LPV: 278% increase; 
RTV: 316% increase; both p < 0.01; Figure 4(d)). In both 
in vitro models, coincubation with TEL partially reversed 
PI-induced upregulation of secreted IL-6 (Figure 4(c) 
and (d)).
Figure 2. Lipid accumulation in differentiating (a) 3T3-F442A 
and (b) primary human adipocytes following incubation with PIs 
with/without TEL or ROSI. ROSI was coincubated with LPV in 
the primary human adipocyte model only. Data are expressed 
as mean (n = 3) ± SD. (*p < 0.01, drug vs vehicle; †p < 0.01, drug 
vs drug + TEL or drug + ROSI.).
Veh: vehicle; RTV: ritonavir; LPV: lopinavir; ATV: atazanavir; TEL: 
telmisartan; ROSI: rosiglitazone.
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TNF-α. LPV (3T3-F442A, 45 pg/mL ± 2.1; primary human 
adipocytes, 62 pg/mL ± 4.2, both p < 0.001) and RTV 
(3T3-F442A, 57 ± 5.0; primary human adipocytes, 
78 ± 5.7, both p < 0.01) but not ATV (3T3-F442A, 
30 ± 2.0; primary human adipocytes, 45 ± 5.0) upregu-
lated secreted TNF-α in comparison to the vehicle-treated 
control (3T3-F442A, 32 ± 4.3, and primary human adipo-
cytes, 40 ± 5.0; Figure 4(e) and (f)). Coincubation with 
either 1 (3T3-F442A) or 5 µM TEL (primary human adipo-
cytes) or 10 µM ROSI (primary human adipocytes only) 
significantly reversed PI-induced upregulation of TNF-α.
Resistin. All three PIs downregulated resistin in both 
murine (LPV: 74% decrease; RTV: 73% decrease; ATV: 
57% decrease; all in comparison to vehicle-treated control; 
p < 0.01; Figure 4(g)) and primary human adipocytes 
(LPV and RTV: 65% decrease; ATV: 48% decrease; all in 
comparison to vehicle-treated control; p < 0.01; Figure 
4(h)). Both TEL and ROSI (in primary human adipocytes 
only) showed a trend to reverse the PI-induced downregu-
lation of resistin, but this was not significant in either of 
these models (Figure 4(g) and (h)).
TEL reverses ARV-induced adipocyte lipolysis 
and inhibition of Akt phosphorylation in primary 
human adipocytes
Both LPV (90% increase; p < 0.03) and RTV (109% 
increase; p < 0.01) but not ATV (23%; p = NS) resulted in 
an increase in free fatty acid levels in the conditioned 
media in primary human adipocytes suggesting enhanced 
lipolysis by these drugs (Figure 5(a)). Coincubation 
with 5 µM TEL reduced PI-induced lipolysis although the 
effect was statistically NS. However, 10 µM ROSI 
showed a significant partial reversal of ARV-induced 
lipolysis.
A significant reduction in the expression of pAktSer473 
was observed with LPV (at 20 µM, 63% reduction, 
p < 0.01) and RTV (at 20 µM, 61% reduction; p < 0.01), 
but not with ATV, in comparison with the vehicle-treated 
controls (Figure 5(b)). Both LPV and RTV reduced pAkt-
Ser473 expression in a dose-dependent manner (see 
Supplementary Information). Coincubation with 5 µM 
TEL or 10 µM ROSI significantly reversed PI-induced 
downregulation of pAktSer473 (Figure 5(b)).
Figure 3. Expression of PPARγ: (a) 3T3-F442A and (b) primary human adipocytes; expression of LPIN1: (c) 3T3-F442A and (d) 
primary human adipocytes, following incubation with PIs with/without TEL or ROSI. ROSI was coincubated with LPV in the primary 
human adipocyte model only. Data are expressed as mean (n = 3) ± SD. (*p < 0.01, drug vs vehicle; †p < 0.01, drug vs drug + TEL or 
drug + ROSI; ‡p < 0.01, preadipocyte vs vehicle.).
Preadipo: preadipocyte; Veh: vehicle; RTV: ritonavir; LPV: lopinavir; ATV: atazanavir; TEL: telmisartan; ROSI: rosiglitazone.
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Figure 4. Adipokine secretion in differentiating 3T3-F442A and primary human adipocytes following incubation with PIs with or 
without TEL or ROSI: adiponectin: (a) 3T3-F442A and (b) primary human adipocytes; IL-6: (c) 3T3-F442A and (d) primary human 
adipocytes and TNF-α: (e) 3T3-F442A and (f) primary human adipocytes; resistin: (g) 3T3-F442A and (h) primary human adipocytes. 
ROSI was coincubated with LPV in the primary human adipocyte model only. Data are expressed as mean (n = 3) ± SD. (*p < 0.01, 
drug vs vehicle; †p < 0.01, drug vs drug + TEL or drug + ROSI; ‡p < 0.01, preadipocyte vs vehicle.).
Preadipo: preadipocyte; Veh: vehicle; RTV: ritonavir; LPV: lopinavir; ATV: atazanavir; TEL: telmisartan; ROSI: rosiglitazone.
Pushpakom et al. 7
Characterisation of optimal TEL dose to elicit 
metabolic effect
Using secreted adiponectin and PPARγ gene as the exem-
plar markers, we evaluated the concentration–response 
relationship of TEL in the presence of LPV (20 µM) in 
primary human adipocytes. TEL significantly reversed 
LPV-induced inhibition of adiponectin at 1, 5 and 10 µM 
concentrations; for PPARγ, the effect of TEL was 
observed at 5 and 10 µM only. Importantly, in both 
instances, the maximal response for TEL was observed at 
5 µM with TEL showing a non-monotonic dose response 
(Figure 6(a) and (b)).
Discussion
We have confirmed the previously reported toxic effect 
of PIs on adipocytes and also identified how PIs affect 
novel adipokines such as LPIN1 and resistin. We also 
found that TEL results in a partial but significant reversal 
of ARV-induced adipocyte toxicity and, for the first time, 
characterised the concentration of TEL that elicits the 
maximal metabolic effect in vitro. We used 3T3-F442A 
cells as they are one of the most widely used in vitro 
models to study adipogenesis and are committed to dif-
ferentiating into adipocytes.20 They have also been shown 
to develop a homogeneous population of mature adipo-
cytes that are morphologically and biochemically similar 
to adipocytes in situ.20 The chronic drug treatment design 
enabled repeated drug exposure to the adipocytes over 
the entire period of adipocyte differentiation; this mim-
icked the in vivo situation where the long-term ARV drug 
treatment may result in cumulative adipocyte toxicity.21 
LPV and RTV were toxic to adipocytes in both in vitro 
models, while ATV, a more lipid-friendly PI,22 was not, 
suggesting that the accumulation of certain ARVs over 
time may reduce cell viability in differentiating adipo-
cyte populations in vivo and potentially deleteriously 
affect the fat cell turnover and thereby adipose tissue 
distribution.
Both LPV and RTV decreased lipid accumulation and 
messenger RNA (mRNA) expression of the adipogenic 
markers, PPARγ and LPIN1, consistent with their anti-
adipogenic effects. By contrast, ATV did not show any 
Figure 5. (a) Lipolysis and (b) expression of pAktSer473 in 
human primary adipocytes following incubation with PIs 
with or without TEL or ROSI. Data are expressed as mean 
(n = 3) ± SD. pAkt expression was adjusted to total Akt and 
data are expressed as mean ratio of absorbance. (*p < 0.01, 
drug vs vehicle; †p < 0.01, drug vs drug + TEL or drug + ROSI.).
Veh: vehicle; RTV: ritonavir; LPV: lopinavir; ATV: atazanavir; TEL: 
telmisartan; ROSI: rosiglitazone.
Figure 6. Dose–response relationship between TEL and 
in vitro metabolic effects: effect of TEL on (a) PPARγ and (b) 
secreted adiponectin over the full concentration range. Data 
are expressed as mean (n = 3) ± SD. (*p < 0.01, drug vs vehicle; 
†p < 0.01, drug vs drug + TEL or drug + ROSI.).
Veh: vehicle; LPV: lopinavir; TEL: telmisartan; ROSI: rosiglitazone.
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effect on any of the above markers of lipid metabolism 
even at a concentration of 20 µM (>4 times its Cmax value 
of 4.4 µM). The contrasting effects of ATV support clinical 
data,22 which show that ATV has very little effect on body 
fat distribution in HIV patients. This is the first study to 
report an effect of PIs on LPIN1, a gene that encodes a 
magnesium-ion-dependent phosphatidic acid phosphohy-
drolase enzyme involved in triglyceride synthesis23 and a 
key factor in the maturation and maintenance of adipocyte 
differentiation.24 LPIN1 is also a key transcriptional 
regulator of PPARγ and various genes involved in lipid 
metabolism.25 Interestingly, LPIN1 mutations cause differ-
ent types of severe human lipodystrophy syndromes26 
although our previous work has failed to identify any asso-
ciation between LPIN1 single-nucleotide polymorphisms 
and HIV lipodystrophy (HIVLD).27 The inhibitory effect 
of lipotoxic PIs on LPIN1 could potentially be one of the 
mechanisms involved in the transcriptional downregula-
tion of PPARγ caused by these drugs.
LPV and RTV had a profound effect on the secretory 
characteristics of the adipocyte regardless of the model 
used. Our results on adiponectin, IL-6 and TNF-α further 
highlight how certain PIs may interact with the adipokine 
network and regulate their transcription leading to adipo-
cyte dysfunction and interference with insulin signalling. 
In addition, LPV and RTV but not ATV showed a signifi-
cant reduction in the expression of phosphorylated form 
of Akt (Ser473); Akt is a serine/threonine kinase and a 
downstream target of phosphoinositide 3-kinase (PI3K) 
signalling, and phosphorylation of its serine residue at 
position 473 is an important step in the insulin signalling 
pathway.28
This study also explored the effects of PIs on resistin, 
an adipocyte-secreted protein which is implicated in IR. 
While higher circulating levels of resistin have been impli-
cated in the development of IR29 and diabetes,30 its role in 
HIVLD is inconclusive. Some cross-sectional studies have 
reported an increase in circulating resistin levels in HIVLD 
patients,31 while other studies failed to find an association32 
or even reported a reduction in resistin levels.33 We 
observed a significant reduction in the amount of resistin 
secreted by the adipocyte with all PIs including ATV 
although the ATV effect was comparatively less than those 
of other PIs. If resistin was involved in IR or adipocyte 
dysfunction, we would have expected its level to increase; 
our results suggest that secreted resistin might not be con-
tributing directly to IR or adipocyte dysfunction in this 
ARV-treated cellular model. Previous clinical studies have 
reported a decrease in plasma resistin with TEL in diabetes 
patients;34 however, neither TEL nor ROSI had any effect 
on resistin in these in vitro models. It should be noted that 
in humans, resistin is primarily produced by cell popula-
tions other than adipocytes,35 including peripheral blood 
mononuclear cells, macrophages and bone marrow cells. 
This could potentially explain the discrepancy in resistin 
levels between clinical and in vitro studies.
TEL is widely used as an antihypertensive because of 
its ability to antagonise the effect of angiotensin II. 
However, TEL is highly lipophilic, and it has been sug-
gested that its off-target effect on PPARγ could be benefi-
cial in the treatment of metabolic disease and CVD.36–38 In 
this study, TEL was able to partially reverse the PI-induced 
inhibition in adipogenesis (lipid accumulation, expression 
of PPARγ and LPIN1), improve PI-induced reduction in 
adiponectin and expression of pAktSer473 (effect on insulin 
sensitivity), and reverse PI-induced upregulation in the 
secretion of proinflammatory markers, IL-6 and TNF-α. A 
previous in vitro study had shown that TEL improves adi-
pocyte function following incubation with ARVs through 
blockade of the adipose RAS.14 It should be noted that 
PPARγ is also a modulator of adipocyte RAS and activa-
tion of PPARγ using full/partial agonists like ROSI or TEL 
could potentially counter the effects of RAS. By testing a 
wide range of concentrations of TEL (0.5–20 µM) on two 
exemplar markers, PPARγ gene and adiponectin protein, 
we observed TEL to show a non-monotonic response with 
the maximal effect observed at 5 µM in the primary human 
adipocyte model. This dose response shown by TEL here 
is different to that seen on blood pressure, which is linear 
and mediated by the angiotensin receptor, AT1R. It might 
very well be that both RAS and PPARγ play an independ-
ent role in the development of PI-induced adipocyte dys-
function; given that PPARγ full agonists such as ROSI 
suffer from serious adverse effects, ARBs such as TEL 
with dual activity on both PPARγ and RAS may offer an 
opportunity to reduce PI-induced toxicity.
Limitations of the study
This study has not investigated the effect of ARVs (with/
without TEL) in mature adipocytes; of course, the adipo-
cyte population in vivo is a mixture of differentiating and 
differentiated adipocytes, but we felt it was important to 
focus on differentiating adipocytes, as harmful effects 
here would ultimately affect the population of differenti-
ated adipocytes. This study did not assess the effect of PI 
drug combinations as used in the clinic; relating the con-
centration–response relationships in vitro to the in vivo 
situation is challenging because of differences that can 
occur in protein binding and drug distribution. It should 
be noted that we have only used three replicates (biologi-
cal replicates) for each experiment in this study, but there 
was a high degree of reproducibility within the experi-
ments. Taken together, our findings support the beneficial 
metabolic effects observed with TEL and open up the 
intriguing possibility that TEL could be used to prevent the 
increase in IR that is seen in HIV-infected individuals 
treated with ARVs.
Pushpakom et al. 9
Conclusion
This study has shown that TEL has beneficial metabolic 
effects on adipocytes when given in combination with PIs 
and therefore has the potential to reverse adipocyte toxic-
ity and IR mediated by PIs. The study also, for the first 
time, has characterised the dose response of TEL in human 
primary adipocytes. These in vitro findings now need to be 
validated in a clinical study which preferably not only 
evaluates, in a randomised fashion, the ability of TEL to 
reduce IR in vivo, but also identifies the optimal dose. This 
is currently being pursued in a phase IIb adaptive design 
clinical trial.39
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